Compare Crispr Therapeutics AG (CRSP) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Kyndryl Holdings Inc — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while Kyndryl Holdings Inc trades at $11.87 (market cap $2.56B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | KD | |
|---|---|---|
Market Cap | $4.97B | $2.56B |
Sector | Health | Technology |
52-Week High | $76.78 | $39.47 |
52-Week Low | $44.34 | $10.59 |
Enterprise Value | $3.32B | $4.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Kyndryl Holdings (KD) trades at $12.32, up 2.92% with a bullish technical signal. The company shows improving fundamentals with 2025 net income turning positive at $252M after years of losses, though recent quarterly earnings missed expectations. Valuation remains attractive with P/E of 14.49 and EV/EBITDA of 3.19. Recent partnerships with Microsoft and AWS for AI solutions highlight strategic positioning.
Outlook remains cautiously optimistic with analyst consensus target of $14.33 offering 16% upside. Key risks include ongoing earnings volatility, internal control investigations, and high debt levels. The transformation toward higher-margin services provides growth potential, but execution risks and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
